Back

Matrix Stiffness Influences Drug Resistance to Gemcitabine Analog and AZD 1775 Combination in PDAC Organoids

2025-06-09 oncology Title + abstract only
View on medRxiv
Show abstract

BackgroundPancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers, with limited therapeutic advancements and rapid development of treatment resistance. Fatty acid-conjugated gemcitabine analogs have shown improved antitumor efficacy. This study investigates the effects of gemcitabine conjugated with caprylic acid (Gemcitabine-8C) in combination with AZD 1775, a WEE1 inhibitor, using patient-derived PDAC organoids. MethodsPatient-derived PDAC cells (G43, G46) were cultured in a ...

Predicted journal destinations